Fig. 1: Neutralization of SARS-CoV-2 by 76E1 in vitro and in vivo.
From: Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
a, The EC50 values of 76E1 binding to the soluble S-ECD proteins of SARS-CoV-2 and its variants of concern, including B.1.1.7, P.1, B.1.351, B.1.617.1, B.1.617.2 and B.1.1.529 (Omicron BA.1). An IAV antibody 28-1253 was included as isotype control (Isoctrl). b, 76E1-mediated neutralization of pseudotyped SARS-CoV-2 and its variants in 293T-hACE2 cells. Unrelated VSV-G pseudovirus was included as a negative control. c, Authentic SARS-CoV-2 neutralization of 76E1 in Vero-E6, HeLa-hACE2 and Calu-3 target cells. n = 3. Representative data are shown from 2 independent experiments (a–c). d–f, Protective efficacy of 76E1 against authentic SARS-CoV-2 infection in hACE2 transgenic mice. d, The mouse study outline. Prophylaxis: the mice were infused with 15 mg kg−1 76E1 (n = 7) or PBS (n = 4) intraperitoneally 1 d before inoculating with 1 × 104 p.f.u. SARS-CoV-2 via intranasal infection. Therapy: the mice were treated with 25 mg kg−1 76E1 8 h after SARS-CoV-2 infection (n = 4). The prophylactic and therapeutic experiments were concurrently conducted and the PBS-administered mice were included as control for both experiments. The mice body weight from prophylactic (e) and therapeutic (f) groups were monitored for 3 d after infection. Lung virus titres of each mouse at 3 d.p.i. were determined by qRT-PCR with 3 replicates. Results are depicted as mean ± s.d. (c,e,f). Two-sided unpaired t-test; ***P < 0.001, ****P < 0.0001.
